An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic Arthritis

NCT00267956 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

146

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriatic Arthritis

Interventions

DRUG: CNTO 1275 63 mg
DRUG: Placebo

Sponsor

Centocor, Inc.